Common Contracts
1 similar null contracts
ProtocolMarch 22nd, 2018
Name of Sponsor/Company: TESARO Name of Investigational Product: TSR-042, bevacizumab, and niraparib Name of Active Ingredient: TSR-042, bevacizumab, and niraparib Title of Study: Phase 2 Multicohort Study to Evaluate the Safety and Efficacy of Novel Treatment Combinations in Patients with Recurrent Ovarian CancerCohort A: PARP Inhibitor-Naïve Platinum-Resistant Ovarian Cancer Treatment Cohort with TSR-042, Bevacizumab, and Niraparib Study center(s): To be determined Principal Investigator: To be determinedInvestigators: To be determined Studied period (years):Estimated date first patient enrolled: Q3 2018 Estimated date last patient completed: Q2 2020 Phase of development: 2 Objectives:Primary:• To evaluate the efficacy of the combination of TSR-042, bevacizumab, and niraparib, as assessed by confirmed objective response rate (ORR), in patients with advanced, relapsed, high-grade ovarian, fallopian tube, or primary peritoneal cancer who have received 1 to 2 prior lines of anticancer t
